Telo Genomics

Name

Telo Genomics

Legal name

Telo Genomics Corp.

Website

https://telodx.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Molecular Diagnostics / Oncology and Neurology Prognostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

Keywords

• Molecular diagnostics
• Telomere profiling tests
• Multiple myeloma prognostics
• Minimal residual disease testing
• Liquid biopsy diagnostics

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Laboratory Testing Services: Telo Genomics operates a CAP-accredited clinical laboratory offering proprietary diagnostic tests including TeloViewSMM. Physicians order tests through the SMART (physician experience) program, with tests processed in the company's Toronto laboratory.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Telo Genomics operates a CAP-accredited, CLIA-certified clinical laboratory offering proprietary molecular diagnostic tests built on its TeloView® 3D telomere profiling platform. Physicians and clinical partners order prognostic and diagnostic tests for Smoldering Multiple Myeloma (TeloViewSMM), Minimal Residual Disease in multiple myeloma (TeloMRD-D and TeloViewNG-MRD), first-line therapy management (TeloViewMM), Alzheimer's disease (TeloViewAD), and prostate cancer risk stratification (TeloViewPC), with tests processed in the company's Toronto laboratory and results returned to ordering physicians.

Product overview

Telo Genomics offers a platform-plus-products architecture centered on its proprietary TeloView® 3D telomere profiling technology. The core TeloView® platform analyzes six telomere parameters from single cells to provide prognostic and diagnostic insights across multiple disease areas. Commercial products include TeloViewSMM for smoldering multiple myeloma risk assessment, TeloMRD-D and TeloView®NG-MRD for minimal residual disease detection in multiple myeloma, TeloViewMM for first-line therapy management, TeloViewAD for Alzheimer's disease identification, and TeloViewPC for prostate cancer risk stratification. The company operates as a molecular diagnostics company with CAP-accredited and CLIA-certified laboratory facilities.

Differentiator

Problem solved

Functional benefit

Brands

• TeloView®: Proprietary 3D telomere analysis platform technology for diagnostics and prognostics in oncology and neurological diseases.

Products and services

• TeloViewSMM Laboratory Developed Test (LDT) prognostic solution for Smoldering Multiple Myeloma (SMM) that quantifies a patient's individual risk of progression from asymptomatic precursor SMM to symptomatic multiple myeloma within 2 years. Validated in collaboration with Mayo Clinic and Dana Farber Cancer Institute in over 170 SMM patients and published in the American Journal of Hematology. Intended for hematologists and oncologists managing SMM patients.
• TeloMRD-D Enumeration-based Minimal Residual Disease (MRD) assay for multiple myeloma that directly counts circulating myeloma plasma cells isolated from peripheral blood using proprietary filtration, immunophenotyping, and fluorescence microscopy. Achieves sensitivity of up to 10^-7 (detecting 1 cancer cell among 10 million cells). Designed for hematologists and oncologists monitoring multiple myeloma patients for residual disease.
• TeloView®NG-MRD Next-generation MRD assay that combines enumeration MRD with proprietary TeloView telomere profiling to assess the malignant potential (disease severity) of identified MRD cells. Goes beyond enumeration to profile the genomic instability of each identified circulating cell, differentiating aggressive clones prone to early relapse from benign clones indicating prolonged remission. Targets multiple myeloma MRD assessment.
• TeloViewMM First-line therapy management test for multiple myeloma that predicts patient response to proposed first-line therapy and identifies relapse risk under standard treatment. Developed in clinical collaboration with Mayo Clinic with a risk scoring algorithm trained on an initial cohort. Designed to inform therapeutic decision-making for hematologists and oncologists, given treatment costs of $125,000-$250,000 per year.
• TeloViewAD Alzheimer's disease identification test designed to work from a non-invasive cheek swab sample. Uses TeloView parameters to identify Alzheimer's disease with high sensitivity and specificity from cheek cells. Predictive clinical algorithm being developed in collaboration with Sunnybrook Hospital. Aimed at neurologists and memory clinics seeking non-invasive tools to identify and stratify AD patients from mild to severe stages.
• TeloViewPC Prostate cancer biopsy-free risk prediction test that stratifies intermediate-risk (Gleason score 7) patients into aggressive versus benign disease categories to support biopsy and surgery decisions. Preliminary predictive risk algorithm is ready and the company is seeking clinical validation partners. Targeted at urologists managing intermediate-risk prostate cancer patients.

Quantifiable outcome

• Sensitivity of 10-7 (detecting 1 cancer cell among 10 million cells) achieved in laboratory-prepared samples, exceeding current clinical sensitivity standards of 10-5 to 10-6
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Eleven partnerships are on record, tiered important, core and minor.

• National and Kapodistrian University of AthensimportantStrategic or Co-development Partner · 14 April 2026Launched retrospective clinical study in April 2026 to validate blood-based assay for MRD testing in multiple myeloma patients. Study aims to demonstrate analytical sensitivity comparable to Euroflow and develop relapse risk scoring model.
• Cleveland CliniccoreStrategic or Co-development Partner · 18 June 2025Initiated new MRD clinical trial for multiple myeloma patients in June 2025. Cleveland Clinic Cancer Institute serves as clinical trial site for validating TeloMRD test.
• Trusted Health AdvisorsimportantImplementation/ SI/ Consulting Partner · 27 February 2025Expanded partnership with Trusted Health Advisors in February 2025. Likely advisory support for US market development and physician engagement strategy.
• Adaptive BiotechnologiesimportantTechnology or Integration · 10 September 2024Validated MRD enumeration assay with Adaptive Biotechnologies in September 2024. Evaluation focused on comparing TeloMRD-D enumeration capabilities with Adaptive's immune sequencing technology.
• Emery PharmaminorStrategic or Co-development Partner · 15 May 2024Collaboration announced May 2024. Details of collaboration scope not specified in available sources.
• Mayo CliniccoreStrategic or Co-development PartnerMajor clinical validation partnership for Smoldering Multiple Myeloma test (TeloViewSMM) validated in over 170 patients. Expanded strategic collaboration in October 2024. Mayo Clinic handles clinical study execution with Telo providing technology platform.
• Dana Farber Cancer InstitutecoreStrategic or Co-development PartnerClinical validation collaboration for TeloViewSMM test in landmark publication in American Journal of Hematology. Dana Farber contributed clinical expertise and patient samples for validation study.
• CancerCare ManitobacoreStrategic or Co-development PartnerTelo Genomics founder Dr. Mai's research laboratory is located within CancerCare Manitoba/Research Institute in Oncology and Hematology. CCMB assigned all IP related to TeloView to Telo Genomics for commercialization. Continued research collaboration ongoing.
• Sunnybrook HospitalimportantStrategic or Co-development PartnerCollaboration for TeloViewAD Alzheimer's disease diagnostic development. Predictive clinical algorithm being developed for identifying Alzheimer's with high sensitivity and specificity from cheek cells.
• Centre for Imaging Technology Commercialization (CIMTEC)coreTechnology or IntegrationCIMTEC, a renowned Canadian imaging-software developer, scaled and validated TeloView software. Critical technology partnership for commercializing the analytical software component.
• Sir Mortimer B. Davis - Jewish General HospitalcoreStrategic or Co-development PartnerTELO-DMRD Clinical Trial (NCT05530096) collaboration with Dr. Rayan Kaedbey as Principal Investigator. Clinical validation site for MRD testing methodology.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Personalis: Cancer genomics company offering tumor profiling and MRD (NeXT Personal). Comparable in stage and market to Telo, focused on tumor-informed MRD and minimal residual disease detection.
• Caris Life Sciences: Molecular profiling company offering comprehensive tumor profiling (MI Profile) and a developing MRD offering. Competes with Telo in advanced molecular characterization of cancer.

Others

• Bio-Techne: Life science tools and diagnostics company whose reagents and assay platforms are used in cancer research. While not a direct MRD competitor, Bio-Techne supplies enabling technologies to the molecular diagnostics ecosystem in which Telo operates.

Direct peers

• Natera: Provider of Signatera, a tumor-informed MRD test used across multiple oncology indications including multiple myeloma. Direct competitor in MRD monitoring with established US payer coverage and broad oncology channel access.
• Adaptive Biotechnologies: Developer of the FDA-approved clonoSEQ MRD test for multiple myeloma and other blood cancers. Direct MRD competitor to Telo's TeloMRD-D and TeloViewNG-MRD; the two companies also formally validated their respective MRD enumeration capabilities together in September 2024.
• Guardant Health: Liquid biopsy company with MRD and oncology monitoring products (Guardant Reveal, Guardant360). Direct competitor in blood-based cancer monitoring, with significantly greater commercial scale and FDA-cleared assays.

Broad incumbents

• NeoGenomics: Established oncology-focused clinical laboratory offering comprehensive molecular and genetic testing including MRD via the RaDaR assay. Competes broadly with Telo in hematology/oncology reference testing.
• Foundation Medicine: Roche subsidiary offering comprehensive genomic profiling of solid tumors (FoundationOne CDx, FoundationOne Liquid CDx). Provides clinical decision support in oncology, partially overlapping with Telo's prognostic/monitoring positioning.
• Myriad Genetics: Established genetic testing company with oncology, women's health, and mental health franchises. Comparable to Telo as a multi-indication genetic/molecular diagnostics company, though at significantly larger scale.
• Exact Sciences: Large molecular diagnostics company with Cologuard and a growing oncology franchise including the Oncodetect MRD test. A scaled competitor with deep commercial channels and FDA-cleared products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/3dsignatures

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Telo Genomics